These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9863870)

  • 41. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
    Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
    J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
    Jackson JB; Becker-Pergola G; Guay LA; Musoke P; Mracna M; Fowler MG; Mofenson LM; Mirochnick M; Mmiro F; Eshleman SH
    AIDS; 2000 Jul; 14(11):F111-5. PubMed ID: 10983633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.
    Witt KL; Cunningham CK; Patterson KB; Kissling GE; Dertinger SD; Livingston E; Bishop JB
    Environ Mol Mutagen; 2007; 48(3-4):322-9. PubMed ID: 17358032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of HIV isolates arising after prolonged zidovudine therapy.
    Mayers DL; McCutchan FE; Sanders-Buell EE; Merritt LI; Dilworth S; Fowler AK; Marks CA; Ruiz NM; Richman DD; Roberts CR
    J Acquir Immune Defic Syndr (1988); 1992; 5(8):749-59. PubMed ID: 1381438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV type 1 zidovudine (ZDV) resistance in blood and uterine cervical secretions of pregnant women.
    Frenkel LM; McKernan J; Dinh PV; Goldman D; Hitti J; Watts DH; Cooper ER; Dragavon J; Coombs RW
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):870-3. PubMed ID: 16989612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1998 Jan; 47(RR-2):1-30. PubMed ID: 9461044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
    Stilianakis NI; Boucher CA; De Jong MD; Van Leeuwen R; Schuurman R; De Boer RJ
    J Virol; 1997 Jan; 71(1):161-8. PubMed ID: 8985335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
    Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
    AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.
    Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Martinez-Picado J; Sutton L; Hazelwood JD; D'Aquila RT
    J Clin Microbiol; 2000 Jul; 38(7):2715-21. PubMed ID: 10878069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations.
    Taylor S; Cane P; Hué S; Xu L; Wrin T; Lie Y; Hellmann N; Petropoulos C; Workman J; Ratcliffe D; Choudhury B; Pillay D
    AIDS Res Hum Retroviruses; 2003 May; 19(5):353-61. PubMed ID: 12803994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV transmitted drug resistance in adult and pediatric populations in Panama.
    Castillo J; Arteaga G; Mendoza Y; Martínez AA; Samaniego R; Estripeaut D; Page KR; Smith RE; Sosa N; Pascale JM
    Rev Panam Salud Publica; 2011 Dec; 30(6):649-56. PubMed ID: 22358417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.